Adagio Medical (ADGM) Director Sean Salmon Receives Option Award

What Happened

• Sean Salmon, a director of Adagio Medical Holdings, was granted a derivative award on 2026-06-16 consisting of options covering 30,000 shares. The Form 4 records an acquisition price of $0.00 for the award (i.e., a grant, not an open-market purchase or sale), and no immediate cash changed hands.

Key Details

• Transaction date: 2026-06-16 (Form 4 filed 2026-08-12 — this filing was late).
• Award: Options covering 30,000 shares reported as a derivative grant (code A).
• Vesting: Per the filing footnote, the option is an annual non-employee director award under the Issuer’s Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan; it vests in equal monthly installments over one year beginning 06/16/2026 (1/12th each month).
• Exercise price / post-transaction holdings: Not specified in the provided filing.
• Filing timeliness: The report was filed ~57 days after the transaction date (late), which reduces immediacy of disclosure and can be a compliance concern.

Context

• This is a standard director compensation grant (an option award), not a purchase or sale that signals a direct market bet. Options must vest and then be exercised (or settled) before shares are acquired or sold, so there is no immediate change in his liquid holdings from this grant alone.